Effectiveness of Artificial IntelliGence-Driven Single-LEad Long-TerM Electrocardiograms MonItoring in Detecting New-Diagnosed Atrial FIbrillation

Recruiting N/A Interventional Study
Atrial Fibrillation (AF)
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
60 and older
Sex
Any
Study type
Interventional
Purpose
Screening
Participants needed
15,360 (estimated)
Sponsor
Beijing Anzhen Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Abstract Purpose: Atrial fibrillation (AF) is a leading cause of stroke and heart failure, yet detection remains suboptimal in rural settings due to limited resources. This study evaluates whether an enhanced screening strategy using artificial intelligence (AI)-integrated 7-day single-lead electrocardiogram (ECG) patches improves AF detection and long-term clinical outcomes compared to routine ca…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: Age 60 years or older No previous history of atrial fibrillation (AF) Willing to participate in random assignment and follow-up Exclusion Criteria: Patients with a pacemaker or implanted cardioverter-defibrillator (ICD) Patients with cognitive impairment or unable to provide i…
Contacts

No contact information available.